MiR-103a targeting Piezo1 is involved in acute myocardial infarction through regulating endothelium function by Huang, Lingzhi et al.
Address for correspondence: Dr Lezhi Li, Department of Nursing, Second Xiangya Hospital, Central South University,  
139 Renmin Road, Changsha, Hunan 410011, China, tel: +86 13807318762, e-mail: 1126511@sina.com
Received: 29.03.2016 Accepted: 18.07.2016
MiR-103a targeting Piezo1 is involved  
in acute myocardial infarction through  
regulating endothelium function
Lingzhi Huang1, 2, Lezhi Li3, Xiaofang Chen4, Huiling Zhang3, Zeya Shi5
1Nursing School, Central South University, Changsha, China 
2Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, China 
3Department of Nursing, Second Xiangya Hospital, Central South University, Changsha, China 
4Department of Nursing, Third Affiliate Hospital, Southern Medical University, Guangzhou, China 
5Intesive Care Unit, Hunan Provincial People Hospital, Changsha, China
Abstract
Background: Acute myocardial infarction (AMI) is commonly known as the heart attack. 
The molecular events involved in the development of AMI remain unclear. This study was to 
investigate the expression of miR-103a in patients with high blood pressure (HBP) and AMI 
patients with and without HBP, as well as its effect on endothelial cell functions.
Methods: MiR-103a expression in plasma and peripheral blood mononuclear cells (PBMCs) 
was measured by real-time polymerase chain reaction (PCR). The regulatory effect of miR-103a 
on Piezo1 gene was identified by a luciferase reporter system. The role of miR-103a in en-
dothelial cells was evaluated by the capillary tube formation ability and cell viability of human 
umbilical vein endothelial cells (HUVECs).
Results: The plasma miR-103a concentration was significantly elevated in patients with 
HBP alone, AMI alone, and comorbidity of AMI and HBP. The miR-103a expression in PBMCs 
in patients with AMI and HBP was significantly higher than the one in healthy controls  
(p < 0.05), however miR-103a expression in PBMCs was not significantly different among 
patients with HBP alone, patients with AMI alone, and healthy controls. MiR-103a targeted 
Piezo1 and inhibited Piezo1 protein expression, which subsequently reduced capillary tube 
formation ability and cell viability of HUVECs.
Conclusions: MiR-103a might be a potential biomarker of myocardium infarction and 
could be used as an index for the diagnosis of AMI. It may be involved in the development 
of HBP and onset of AMI through regulating the Piezo1 expression. (Cardiol J 2016; 23, 5: 
556–562)
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Introduction
Myocardial infarction, commonly known as 
the heart attack, is a leading cause of mortality in 
many industrialized countries [1]. Acute myocardial 
infarction (AMI) occurs when one of the arteries that 
supply the myocardium is blocked due to acute clot 
formation. The blockage results in necrosis of myo-
cardial tissue and loss of myocardium function [2]. 
However, the molecular events involved in the 
development of AMI are still unclear. Identifica-
tion of molecular markers for AMI may uncover 
important triggers involved in the progression 
of atherosclerotic vascular diseases. Moreover, if 
a marker can be used to give an early and accurate 
diagnosis of AMI, it will allow immediate initiation 
of therapy and reduce the mortality rate.
MicroRNAs (miRNAs) are a family of en-
dogenous, short (17–25 nucleotides) non-coding 
RNAs. MiRNAs are commonly thought to regulate 
gene expression at the post-transcriptional level 
through binding to the 3’-untranslated regions of 
the mRNA and subsequently inhibiting its transla-
tion or inducing its degradation [3]. Bioinformatic 
analysis predicted that more than 60% of human 
genes are targets of miRNAs [4]. Moreover, the 
accumulated evidence has demonstrated that 
over 100 circulating miRNAs can be detected in 
healthy individuals [5]. Although the exact origins 
and biological functions of circulating miRNAs are 
still unclear, many studies revealed that circulating 
miRNAs could be markers of disease progression, 
prognosis, or diagnosis.
Several miRNAs have been shown to be asso-
ciated with the pathophysiological consequences of 
AMI [6]. For example, a study by Long et al. [7] dem-
onstrated that plasma concentration of miR-30a, 
miR-195, and let-7b are potential indicators of 
AMI. Other study, by Wang et al. [8], showed that 
plasma miR-21-5p and miR-361-5p expressions 
were significantly increased, whereas miR-519e-5p 
expression was reduced in AMI patients. However, 
the identification of circulating miRNA in AMI 
yielded inconsistent findings.
A recent study first identified miR-103a as 
a mechanosensitive miRNA that regulates osteo-
blast differentiation by directly targeting Runx2 [9]. 
The Piezo1 gene has recently been  found to be 
important for normal shear stress-evoked Ca2+ 
signaling and non-selective cationic channel activ-
ity in endothelial cells. Piezo1 channels can func-
tion as pivotal integrators in vascular biology [10, 
11]. In addition, bioinformatic analysis predicts that 
Piezo1 is a target of miR-103a, but this prediction 
has not been validated yet, particularly, the role 
of miR-103a in AMI. We therefore hypothesize 
that miR-103a may be involved in cardiovascular 
diseases through regulating Piezo1 expression in 
endothelium.
In this study, the circulating miR-103a con-
centration was compared between patients with 
high blood pressure (HBP), AMI, and comorbidity 
of AMI and HBP. The relationship between miR- 
-103a and Piezo1, as well as their biological activity, 
were identified in human umbilical vein endothelial 
cells (HUVEC).
Methods
Participants
Forty-five patients with HBP, 81 patients with 
AMI (including 38 patients without a history of 
HBP), and 47 age-matched healthy controls were 
recruited at Department of Cardiology, Second 
Xiangya Hospital, Central South University from 
September 2013 to December 2014. Routine ex-
aminations, such as blood glucose, lipid profile, ho-
meostasis, blood pressure, and electrocardiography 
were performed in each AMI patient immediately 
after admission. Routine examination in HBP pa-
tients included blood glucose, lipid profile, homeo-
stasis, and blood pressure tests. AMI was diagnosed 
according to published standards [12]. Briefly, the 
inclusion diagnosis criteria were the following: 
1) acute ischemic-type chest pain within 24 h; 
2) positive electrocardiogram changes suggesting 
AMI (new ST-T changes, new left bundle branch 
block, or new pathological Q-wave changes); and 
3) elevated plasma cardiac troponin I (> 0.1 ng/mL). 
HBP was determined by 3 examinations at the 
same time in 3 consecutive days. The blood pres-
sure data of AMI patients were obtained from pa-
tient medical records and the most recent record 
was adopted. All patients with a history of atrial 
fibrillation, myocardial infarction, hemorrhagic 
stroke, or recurrent stroke and comorbidity with 
tumor, acute infectious disease, blood disease, 
and renal or liver failure were excluded from the 
study. This study was pre-approved by the Ethics 
Committee for Human Research, Central South 
University, and written consent forms were ob-
tained from all participants.
Blood sample collection and RNA extractions
In AMI patients, blood was collected imme-
diately at admission. In HBP patients and healthy 
controls, fasting blood was collected. A sample of 
10 mL of whole blood was collected into tubes with 
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EDTA anticoagulant, and plasma was isolated from 
the blood by centrifugation at 1,000 g for 10 min at 
room temperature. At the same time, peripheral 
blood mononuclear cells (PBMCs) were isolated 
using Ficoll-400 [13]. Total RNA in plasma and 
PBMCs was isolated using TRIzol reagent (Life 
Technologies, Carlsbad, CA, USA) according to the 
manufacture protocol. The concentration of total 
RNA was measured using a NanoDrop 1000 spec-
trophotometer (Thermo Scientific, Utah, USA).
Real-time quantitative PCR
Reverse transcription was performed using 
TaqMan miRNA RT Kit (Applied Biosystems, Fos-
ter City, USA) by following the manufacturer’s pro-
tocol. The expression of miRNA-103a was analyzed 
by real-time (RT) polymerase chain reaction (PCR) 
using a TaqMan® miRNA assay kit (Life Technolo-
gies, USA). The primers for amplifying miR-103a 
were designed, as previously described [14]. The 
amplification of each sample was triplicated. The 
expression of miRNAs was analyzed using the 2-DDCt 
method. Spiked-in caenorhabditis elegans miRNA 
(cel-miR-39) was used as an internal control for 
quantitative RT-PCR, as previously described [15]. 
The relative changes in folds compared to the basal 
expression were used for data analysis.
Cell culture
Human umbilical vein endothelial cells (HU-
VECs) and 293T cell lines were provided by the 
Shanghai Institute of Cell Biology (China) and 
cultured in DMEM/F12 medium containing 10% 
fetal bovine serum at 37°C, 5% CO2.
Luciferase reporter assay
Human Piezo1 cDNA 3’-UTR (NM_001142864) 
containing the putative binding site of miR-103a 
was amplified by PCR from a cDNA library pre-
pared from human tissues. The 273bp fragment 
was amplified using forward primer: 5’-GAGTAG-
GAGCTGCTGCTGGC-3’ and reverse primer: 
5’-TCTGATTGTCCATTTGTATAAAT-3’ and in-
serted into the Spe I and Hind III sites of luciferase 
reporter vector pmiR-REPORTTM (Life Technolo-
gies, USA). The insertion was sequenced using 
primers provided with the reporter vector. The 
produced reporting plasmid was named pmiR-
-Piezo1. 293T cells (1 × 106) were plated in 10 cm 
dishes 24 h before transfection. The commercially 
synthesized miR-103a (Life Technologies, USA) 
was co-transfected with pmiR-Piezo1 plasmid 
DNA or pmiR- REPORTTM blank plasmid DNA (1:1 
mixture) using Lipofectamine 2000 (Life Technolo-
gies). Twenty-four hours later, luciferase activities 
were consecutively measured using a Luciferase 
1000 Assay System (Promega, USA) according to 
the user manual.
Western blot of Piezo1 protein expression
HUVECs in 10-cm dishes were grown to 
60% confluency and then transfected with 10 mM 
of miR-103a or 10 mM of cel-miR-39 using lipo-
fectamine 2000 by following the manufacturer’s 
manual. Forty-eight hours later, cells were har-
vested, homogenized, and subjected to Western 
blot analysis of Piezo1 protein expression follow-
ing the previous protocol [16]. Briefly, the treated 
HUVECs were homogenized in lysis buffer (1% 
SDS, 10 mM Tris pH 8.0, 130 mM NaCl, 5 mM 
EDTA) containing protease inhibitors. 30 µg of total 
protein was separated on 4–15% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE) gels and transferred onto polyvinylidene 
fluoride (PVDF) membranes. After blocking with 
phosphate buffered saline (PBS) buffer containing 
0.1% Tween-20 (PBST) and 5% non-fat milk for 
30 min, membranes were incubated with rabbit 
anti-human Piezo1 antibody (Novus Biologicals, 
Littleton, CO, USA) at room temperature for 2 h, 
followed by washing with PBST for 3 × 10 min, 
and incubation with goat-anti-rabbit IgG antibody 
(Novus Biologicals) for 2 h at room temperature. 
Immunoreactive bands were detected using a chemi-
luminescent reagent (Pierce, Rockford, IL, USA). To 
control for loading efficiency, the blots were stripped 
and re-probed with a-tubulin antibody (Cell Signal-
ing Technology, Danvers, MA, USA).
Tube formation assay
HUVECs in 10-cm dishes were transfected with 
10 mM of miR-103a, or cel-miR-39 by lipofectamine 
2000. Forty-eight hours later, cells were trypsinized 
and resuspended in cultured medium containing 
1.5% fetal bovine serum. The tube formation assay 
was conducted in 24-well plates coated with 200 µL 
of ECMatrix™ (Millipore, Billerica, MA, USA) 
by following the manufacturer’s instructions. Cells 
(1 × 105 cells/well) were then plated onto matrigel-
coated plates and incubated at 37°C, 5% CO2 for 
12 h to allow tube formation and tube formation was 
evaluated under a light microscope.
Cell viability assay
1 × 104 HUVECs were seeded into each well of 
a 96-well plate. Cells were transfected with 10 mM 
of miR-103a or cel-miR-39 by lipofectamine 2000. 
Forty-eight hours later, the 3-(4,5-dimethylthiazol-
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2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say was performed as previously described [17]. 
The decrease in cell viability was calculated as the 
percentage of absorbance in the non-transfected 
control (blank control).
Statistical analysis
Data were presented as mean ± standard 
deviation of the mean (SEM) and analyzed with 
SPSS 13.0 software. Chi-square statistics (c2 test) 
were used for analyzing quantitative data. One-
way ANOVA (LSD-t) was used for the comparison 
among the three groups. A p < 0.05 was considered 
statistically significant.
Results
Clinical and laboratory characteristics
The general characteristics of patients and 
healthy controls are presented in Table 1. No 
significant differences in age, sex, fasting glucose, 
total cholesterol, low density lipoprotein, high den-
sity lipoprotein, or triglyceride level were observed 
between patients with HBP and AMI, and patients 
with AMI and HBP, and the healthy controls. How-
ever, significantly higher systolic blood pressure 
was observed in the two groups of patients with 
HBP compared to the healthy controls.
The concentration of plasma miRNA-103a
The concentrations of plasma miR-103a in 
patients with HBP (p < 0.05), AMI (p < 0.01), 
and AMI with HBP (p < 0.001) were significantly 
higher than that in the healthy controls. The con-
centration of plasma miR-103a in patients with AMI 
alone was significantly higher than that in patients 
with HBP alone (p < 0.05), while miR-103a concen-
trations in patients with AMI and HBP were signifi-
cantly higher than those in patients with AMI alone 
(p < 0.05) and patients with HBP alone (p < 0.01) 
(Fig. 1A). In contrast, the miR-103a expressions in 
PBMCs were not significantly higher in patients 
with HBP alone and patients with AMI alone, 
compared to healthy controls. The miR-103a ex-
pression in PBMCs in patients with AMI and HBP 
was significantly higher than that in the healthy 
controls (p < 0.05), but not significantly different 
from that in patients with HBP alone and patients 
with AMI alone (p > 0.05) (Fig. 1B).
Piezo1 is a target of miR-103a
A previous study suggested that miR-103a 
is a mechanosensitive miRNA [9]. The computer 
informatics assay showed that Piezo1 is a target of 
miR-103a (Fig. 2A). We further validated whether 
Piezo1 is a target of miR-103a. Luciferase reporter 
assay was used to investigate the regulatory effect 
of miR-103a on Piezo1 expression. The results 
showed that co-transfection of synthesized miR-
-103a with pmiR-Piezo1 plasmid, but not pmiR-
-REPORT blank plasmid significantly decreased 
luciferase activity in 293T cells (Fig. 2B). To test 
whether miR-103a regulates Piezo1 expression in 
HUVECs, cells were transfected with miR-103a, 
Table 1. Clinical characteristics of patients.
Characteristics AMI + HBP
(n = 43)
AMI
(n = 38)
HBP
(n = 45)
HC
(n = 47)
Age [years] 56 ± 12 55 ± 11.4 57 ± 11.5 50 ± 10.1
Male/female 30/13 26/12 27/18 28/19
Hyperlipidemia 5 (11.6%) 5 (13.2%) 3 (6.7%) 1 (2.1%)
Fasting glucose [mmol/L] 6.6 ± 1.82 6.2 ± 1.33 6.1 ± 1.9 5.7 ± 1.7
SBP [mm Hg] 143 ± 17* 121 ± 14 149 ± 18* 121 ± 16
DBP [mm Hg] 88 ± 13 80 ± 14 84 ± 15 77 ± 14
TC [mmol/L] 4.4 ± 0.9 4.3 ± 0.8 4.3 ± 1.0 4.2 ± 0.8
TG [mmol/L] 1.41 ± 1.0 1.42 ± 0.64 1.58 ± 1.4 1.6 ± 1.3
HDL [mmol/L] 1.04 ± 0.27 1.05 ± 0.26 1.22 ± 0.33 1.26 ± 0.32
LDL [mmol/L] 2.71 ± 0.85 2.66 ± 0.77 2.5 ± 0.75 2.4 ± 0.63
WBC [× 109/L] 8.03 ± 2.2 8.0 ± 2.7 6.7 ± 1.52 6.6 ± 1.43
Cr [μmol/L] 98.4 ± 34 93 ± 48 68 ± 27 58 ± 21
*p < 0.05 vs. healthy controls; AMI — acute myocardial infarction; Cr — creatinine; DBP — diastolic blood pressure; HBP — high blood  
pressure; HDL — high-density lipoprotein; LDL — low-density lipoprotein; SBP — systolic blood pressure; TC — total cholesterol; TG —  
total triglyceride; WBC — white blood cell
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or cel-miR-39. Western blot showed that HUVECs 
transfected with miR-103a inhibited Piezo1 protein 
expression, compared to blank and cel-miR-39 
controls (Fig. 2C). These results suggested that 
Piezo1 is a target of miR-103a in endothelial cells.
Inhibition of capillary tube formation and 
cell viability in HUVEC by overexpression 
of miR-103a
Piezo1 has been demonstrated to regulate the 
cationic channel activity in endothelial cells [10]. 
The effect of miR-103a on the ability of HUVEC 
to form capillary-like structures was tested. As 
shown in Figure 3A, HUVEC grew on matrigel 
formed complex network of capillary tubes after 
12 h. Transfection with miR-103a significantly 
inhibited and disrupted capillary tube formation 
(Fig. 3A, 3B). We further tested effects of miR-103a 
on cell viability. MTT assay showed that trans-
fection of miR-103a significantly decreased cell 
viability (Fig. 3C). The transfection efficacy of 
miR-103a was validated by RT-PCR of miR-103a 
expression (Fig. 3D).
Discussion
Previous studies have reported that numer-
ous circulating miRNAs are involved in AMI and 
some of them are thought to be cardiac-specific 
[18–21] and others non-specific [22, 23]. However, 
previous studies provided no evidence for the 
pathophysiological functions of these miRNAs in 
the development of AMI. This study demonstrated 
that plasma miR-103a is increased in patients with 
HBP although it is more significantly increased in 
AMI patients. The in vitro study further revealed 
that miR-103a regulated Piezo1 expression and 
subsequently affected function of endothelial cells. 
This study suggests that elevated miR-103a might 
be not only a biomarker for AMI, but also an etio-
logical factor for the development of cardiovascular 
diseases, including AMI.
In this study, miR-103 was significantly el-
evated in the plasma of patients with HBP alone. 
This suggests that elevated miR-103a is associ-
ated with HBP and may exist before the onset of 
AMI. In AMI patients with or without HBP, plasma 
miR-103a concentrations were more significantly 
elevated. In contrast, there were no significant 
differences in miR-103a expressions in periph-
eral blood mononuclear cells among three patient 
groups. This implies that peripheral blood cells may 
not be the source of plasma miR-103a. However, 
this study also provided no evidence whether the 
elevated plasma miR-103a came from the necrotic 
myocardium. In addition, it is difficult to monitor 
the plasma miR-103a concentration before AMI. 
Also, blood was collected in AMI patients immedi-
Figure 1. MiR-103a expression in plasma and peripheral blood mononuclear cells (PBMCs). MiR-103a in plasma and 
PMBCs was measured by real-time polymerase chain reaction and relative expression was calculated; A. MiR-103a 
expression in plasma, *p < 0.05, #p < 0.01, **p < 0.001 vs. healthy control, †p < 0.05 vs. high blood pressure (HBP); 
‡p < 0.05 vs. acute myocardial infarction (AMI); B. MiR-103a expression in PMBC, *p < 0.05 vs. healthy control, healthy 
controls (n = 47), HBP (n = 45), AMI (n = 38), AMI with HBP (n = 43).
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Figure 3. The effects of miR-103a on tube formation and cell viability in human umbilical vein endothelial cells 
(HUVECs). A. Representative tube formation images. Complex network of tubes were seen in blank and cel-miR-39 
controls; B. Quantitative analysis of tube formation. miR-103a transfection significantly decreased tube formation, 
**p < 0.001 vs. other groups, n = 5; C. MTT assay of cell viability. Transfection of miR-103a significantly reduced cell 
viability in HUVECs, **p < 0.001 vs. other groups, n = 4. D. Real-time polymerase chain reaction of miR-103a expres-
sion in HUVECs, **p < 0.001 vs. other groups; n = 4.
Figure 2. The regulatory effect of miR-103a on Piezo1 expression. A. Bioinformatic analysis of miR-103a targeting site 
on Piezo1 sequence; B. Luciferase reporting assay. Co-transfection of miR-103a with pmiR-Piezo1 plasmid signifi-
cantly reduced luciferase activity, n = 5, **p < 0.001 vs. other groups; C. Western blot of Piezo1 protein expression 
in human umbilical vein endothelial cells (HUVECs). Transfection of miR-103a obviously decreased Piezo1 protein 
expression in HUVECs, n = 4, **p < 0.001 vs. other groups.
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ately at admission, yet fasting blood was collected 
from HBP patients and healthy controls. It is un-
clear whether fasting may alter the expressions of 
miR-103a. Thus, the diagnostic value of elevated 
plasma miR-103a concentrations in AMI patients 
may need further evidence because they were 
only compared to healthy controls, but not with 
the expression before the onset of AMI.
Piezo1 protein has been identified as an essen-
tial component of mechanically activated channels 
and induces cationic non-selective mechanically 
activated currents [24, 25]. The role of Piezo1 gene 
has been linked recently to the vascular biology [11]. 
Piezo1 channels have been revealed to be sensors of 
blood flow through shear-stress-evoked ionic cur-
rent and calcium influx in endothelial cells, which 
regulate the spatial reorganization of endothelial 
cells to the polarity of the applied force [11]. This 
study revealed that miR-103a directly targeted the 
Piezo1 gene and inhibited its expression in HU-
VECs. Artificial overexpression of miR-103a also 
inhibited capillary tube formation and cell viability 
in HUVECs. Thus, elevated miR-103 expression 
in patients with HBP may cause low expression of 
Piezo1 in endothelial cells and subsequent inhibi-
tion of endothelium function. This may be involved 
in the progression of cardiovascular diseases and 
the onset of AMI. However, this study provided 
no evidence on whether elevated miR-103a leads 
to a decrease in Piezo1 gene expression in the en-
dothelium of patients with HBP and subsequently 
decreases the sensitivity of endothelium to blood 
pressure. It is widely known that a single miRNA 
can target numerous genes. Therefore, besides 
the Piezo1 gene, it is unclear how many miR-103a-
-regulated genes are involved in its regulatory ef-
fects on the biological functions of endothelial cells. 
Further studies need to be conducted to clarify the 
role of miR-103a and Piezo1 in the development of 
cardiovascular diseases.
Conclusions
In conclusion, this study suggests that miR- 
-103a might be an etiological factor of HBP through 
regulating Piezo1 gene expression. Mir-103a could 
be a biomarker for cardiovascular diseases, includ-
ing HBP and AMI.
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